US Earnings Financial Results SEC Filings — May 26, 2026

26-05-2026

T-REX Acquisition Corp. (TRXA) reported a net loss of $1,169,000 for the three months ended March 31, 2026, widening from a $394,000 loss in the prior-year quarter, while total revenue fell sharply to $705,000 from $8,226,000. For the nine-month period, the net loss more than doubled to $2,579,000 from $1,123,000, driven by a gross loss of $121,058 and operating expenses of $2,509,000. The company's cash position deteriorated to just $383 as of March 31, 2026, from $49,733 at June 30, 2025, and total liabilities exceeded total assets, resulting in a stockholders' deficit of $1,248,000.

• · Mining revenue for the three months ended March 31, 2026 was $774, down from $953 in the prior-year period.
• · Hosting revenue was $0 for the three months ended March 31, 2026, compared to $7,294 in the prior-year period.
• · Realized loss on bitcoin held was $69 for the three months ended March 31, 2026, versus a loss of $21 in the prior-year period.
• · Cost of goods sold for the three months ended March 31, 2026 was $24,983, up from $11,866 in the prior-year period.
• · Gross loss for the three months ended March 31, 2026 was $24,278, compared to a gross loss of $3,640 in the prior-year period.
• · Operating expenses for the three months ended March 31, 2026 were $1,306,232, up from $375,255 in the prior-year period.
• · Share-based compensation for the three months ended March 31, 2026 was $377,503, up from $54,279 in the prior-year period.
• · Administration fees for the three months ended March 31, 2026 were $701,566, up from $144,098 in the prior-year period.
• · Gain on derivative liabilities for the three months ended March 31, 2026 was $234,100, compared to a gain of $1,453 in the prior-year period.
• · Net cash used in operating activities for the nine months ended March 31, 2026 was $232,605, compared to $506,679 in the prior-year period.
• · Net cash provided by financing activities for the nine months ended March 31, 2026 was $195,586, compared to $759,067 in the prior-year period.
• · The company had a stockholders' deficit of $1,247,698 as of March 31, 2026, compared to $1,089,187 as of June 30, 2025.
• · Total liabilities exceeded total assets by $1,247,698 as of March 31, 2026.
• · The company's accumulated deficit was $12,138,463 as of March 31, 2026, up from $9,559,350 as of June 30, 2025.
• · The company had $20,834 in stock subscription payable as of March 31, 2026, down from $319,018 as of June 30, 2025.
• · The company had $1,995,852 in deferred stock compensation (contra equity) as of March 31, 2026, up from $26,666 as of June 30, 2025.
• · The company's weighted average common shares outstanding for the three months ended March 31, 2026 was 27,187,425, up from 21,075,694 in the prior-year period.
• · Basic and diluted net loss per share for the three months ended March 31, 2026 was $0.04, compared to $0.02 in the prior-year period.
• · For the nine months ended March 31, 2026, the Holding segment had a net loss of $2,287,079, the Mining segment had net income of $6,819, and the Hosting segment had a net loss of $298,851.
• · As of March 31, 2026, the Holding segment had total assets of $107,122, the Mining segment had $76,436, and the Hosting segment had $486,845.
• · As of March 31, 2026, the Holding segment had total liabilities of $879,597, the Mining segment had $120,897, and the Hosting segment had $917,608.

26-05-2026

Global Interactive Technologies, Inc. (GITS) filed its 10-K annual report for the fiscal year ended May 26, 2026, detailing its monetization model centered on Vote & Boost sales, premium subscriptions, and scalable advertising. The company continues to incur recurring losses, has a working capital deficiency, and its auditors have expressed substantial doubt about its ability to continue as a going concern, requiring significant additional capital. Despite these risks, GITS is expanding its IP portfolio (including music distribution and The Nut Job 3) and leveraging a user-centric economy with 50% of daily net advertising profits distributed as FP to users.

• · The company's auditors have stated that substantial doubt exists about its ability to continue as a going concern.
• · The company has incurred recurring losses from operations and has a working capital deficiency.
• · The company requires significant additional capital to continue as a going concern.
• · The value of FP is maintained at a fixed ratio of 1 FP to 100 Korean Won.
• · The company expanded its IP portfolio in 2025 to include distribution of music for K-pop artists and international animation projects such as The Nut Job 3.
• · The real-time translation engine currently supports 17 languages.
• · Communications are protected through end-to-end encryption (E2EE).
• · New communities are automatically activated when user requests for a specific topic reach a strategic threshold.
• · The company plans to produce 2-minute short-form cultural content for distribution on Faning and third-party social media networks.

26-05-2026

CSW Industrials reported net revenues of $1,082.5M for fiscal year 2026, a 23.3% increase from $878.3M in 2025, driven by strong growth in its largest segment. However, operating income declined 7.0% to $168.5M from $181.2M, and operating margin contracted to 15.6% from 20.6%, reflecting higher SG&A expenses and a loss in one segment. Net cash from operations also fell 11.1% to $149.7M, while investing activities surged due to a $1.04B cash outflow.

• · Segment A (largest) revenues grew 31.3% YoY to $810.3M, but its operating margin fell to 21.7% from 26.9%.
• · Segment B revenues increased 8.4% to $160.1M, yet operating margin declined to 13.8% from 15.4%.
• · Segment C revenues declined 1.0% to $119.9M and swung to an operating loss of $1.2M from a profit of $19.2M.
• · SG&A expenses rose 34.5% to $285.1M, outpacing revenue growth, and as a percentage of revenue increased to 26.3% from 24.1%.
• · Net cash used in investing activities surged to $1.04B from $102.2M, likely reflecting a major acquisition or capital expenditure.
• · Financing activities provided $701.5M in cash, compared to $138.0M in 2025, indicating significant debt or equity issuance.

26-05-2026

Champion Homes, Inc. (SKY) reported net sales of $2,663.6M for the fiscal year ended March 28, 2026, up 7.3% from $2,483.4M in the prior year, driven by a 6.7% increase in U.S. manufacturing and retail net sales and a 17.9% jump in Canadian manufacturing net sales. Net income attributable to Champion Homes grew 4.3% to $206.9M, while Adjusted EBITDA rose 8.1% to $308.2M. However, gross profit margin contracted slightly to 26.4% from 26.7%, and the company recorded $5.8M in plant closure costs and $5.0M in product liability costs related to water intrusion, partially offset by a $3.7M gain on sale of an idle facility.

• · U.S. manufacturing and retail average home selling price rose 4.8% to $97.8 thousand from $93.3 thousand.
• · Canadian manufacturing average home selling price increased 2.3% to $122.8 thousand from $120.0 thousand.
• · U.S. Factory-built Housing gross profit grew 3.9% to $641.6M; Canadian Factory-built Housing gross profit surged 34.7% to $32.1M.
• · Selling, general, and administrative expenses increased 6.0% to $452.6M, with Canadian Factory-built Housing SG&A up 52.7%.
• · Interest income decreased 5.7% to $24.0M, while interest expense declined 10.9% to $7.5M.
• · Average cash balance increased 12.9% to $624.3M from $552.7M.
• · Depreciation and amortization rose 14.0% to $47.8M.
• · The company recorded $5.8M in plant closure costs, $5.0M in product liability costs (water intrusion), and $1.8M in transaction costs in fiscal 2026, with no such costs in the prior year.
• · Gain on sale of idle facility was $3.7M in fiscal 2026 versus none in fiscal 2025.
• · Change in fair value of contingent consideration decreased 47.8% to $4.5M from $8.6M.
• · Equity in net (income) loss of ECN swung from a loss of $0.4M in fiscal 2025 to income of $1.2M in fiscal 2026.
• · Net income attributable to non-controlling interest more than doubled, increasing 126.2% to $7.3M.
• · Effective tax rate was essentially flat at 21.0% versus 20.9%.

26-05-2026

Zscaler reported revenue of $850.5M for Q3 FY2026 (April 30, 2026), up 25.4% YoY from $678.0M, and $2,454.3M for the nine months, up 25.6% YoY. However, net loss widened to $13.9M (from $4.1M) in Q3 and to $59.8M (from $23.9M) year-to-date, driven by higher operating expenses and a provision for income taxes. Total assets grew to $7.1B, supported by acquisitions (goodwill increased to $1.09B), while cash and equivalents declined sharply to $982.1M from $2.39B at July 31, 2025.

• · Gross profit for Q3 FY2026 was $657.8M (77.3% margin) vs $522.1M (77.0% margin) in Q3 FY2025.
• · Sales and marketing expenses rose to $371.9M in Q3 FY2026 from $314.6M in Q3 FY2025, a 18.2% increase.
• · Research and development expenses increased to $232.3M in Q3 FY2026 from $169.8M in Q3 FY2025, up 36.8%.
• · General and administrative expenses grew to $83.2M in Q3 FY2026 from $63.1M in Q3 FY2025, up 31.9%.
• · Loss from operations widened to $29.6M in Q3 FY2026 from $25.4M in Q3 FY2025.
• · Interest income was $34.0M in Q3 FY2026 vs $31.3M in Q3 FY2025.
• · Provision for income taxes increased to $11.5M in Q3 FY2026 from $8.7M in Q3 FY2025.
• · Total assets grew to $7.10B as of April 30, 2026 from $6.42B as of July 31, 2025.
• · Deferred revenue (current) increased to $2.10B from $2.05B.
• · Convertible senior notes remained stable at $1.70B.
• · Accumulated deficit increased to $1.25B from $1.19B.
• · Stock-based compensation for the nine months ended April 30, 2026 was $617.4M, up from $507.9M in the prior period.
• · Other comprehensive loss was $22.9M in Q3 FY2026 vs other comprehensive income of $38.5M in Q3 FY2025.

26-05-2026

Kailera Therapeutics reported a net loss of $78.9M for Q1 2026, compared to $18.0M in Q1 2025, driven by a significant increase in R&D expenses to $70.9M from $10.1M, primarily due to external research costs for ribupatide injection. Total assets decreased to $624.8M from $692.3M at year-end 2025, while cash and cash equivalents fell to $111.8M from $160.3M. The company had an accumulated deficit of $447.5M as of March 31, 2026.

• · External R&D for ribupatide injection was $50.6M in Q1 2026 vs $4.5M in Q1 2025.
• · Stock-based compensation expense was $3.9M in Q1 2026 vs $1.5M in Q1 2025.
• · Net cash used in operating activities was $68.3M in Q1 2026 vs $18.2M in Q1 2025.
• · Total stockholders' deficit was $432.1M at March 31, 2026 vs $356.5M at December 31, 2025.
• · Weighted-average common stock outstanding (basic and diluted) was 21,607 shares in Q1 2026 vs 1 share in Q1 2025.

26-05-2026

Veradigm Inc. reported a net loss of $291.6M for FY2024, a sharp reversal from net income of $49.2M in FY2023, driven by a $108.2M goodwill impairment, a 5.0% revenue decline to $594.4M, and a significant increase in SG&A expenses. All three segments (Provider, Payer, Life Sciences) experienced revenue and gross profit declines in FY2024, while the company also posted a net loss of $128.9M in Q1 2024 and $153.6M in H1 2024.

• · FY2024 effective tax rate was 32.3%, up from 17.8% in FY2023.
• · FY2024 equity in net loss of unconsolidated subsidiaries was $7.2M, compared to $0.3M in FY2023.
• · FY2024 non-operating expense was $20.3M vs non-operating income of $25.5M in FY2023.
• · FY2024 amortization of intangibles was $11.0M, up from $8.7M in FY2023.
• · FY2024 cost of revenue increased to $292.2M from $284.5M in FY2023.
• · Q1 2024 effective tax rate was 11.7%, down from 67.8% in Q1 2023.
• · Q2 2024 effective tax rate was 7.4%, down from 28.8% in Q2 2023.
• · Q3 2024 effective tax rate was 10.9%, down from 18.3% in Q3 2023.
• · FY2024 Provider segment gross profit was $242.0M, down from $269.5M in FY2023.
• · FY2024 Payer segment gross profit was $33.4M, down from $38.6M in FY2023.
• · FY2024 Life Sciences segment gross profit was $26.9M, down from $33.5M in FY2023.
• · FY2023 revenue grew 6.4% vs FY2022, and gross profit grew 10.7%.
• · FY2023 net income was $49.2M vs a net loss of $86.5M in FY2022.
• · FY2023 SG&A was $200.9M, up from $169.2M in FY2022.
• · FY2023 R&D was $97.0M, roughly flat vs $97.9M in FY2022.
• · FY2023 impairment of goodwill was $0.2M vs $7.5M in FY2022.
• · FY2023 amortization of intangibles was $8.7M, down from $60.9M in FY2022.
• · FY2023 non-operating income was $25.5M vs a $35.6M expense in FY2022.
• · FY2023 effective tax rate was 17.8%, down from 69.9% in FY2022.
• · FY2023 equity in net loss of unconsolidated subsidiaries was $0.3M vs $1.1M in FY2022.
• · FY2022 discontinued operations loss was $66.4M; none in FY2023 or FY2024.

26-05-2026

Digital Turbine, Inc. reported a net loss of $37.7M for the fiscal year ended March 31, 2026, a significant improvement from a net loss of $92.1M in the prior year, driven by a 15.2% revenue increase to $565.3M and a 2.5% reduction in total operating expenses. However, the company faced a sharp increase in net interest expense (up 68.4% to $58.6M) and a $9.8M loss on debt extinguishment, while operating cash flow surged 251.9% to $41.8M.

• · Revenue share costs increased 3.5% YoY to $243.6M, while other direct costs of revenue rose 36.0% to $47.0M.
• · Product development expenses grew 2.6% to $40.5M, but sales and marketing declined 5.9% to $58.0M.
• · General and administrative expenses fell 18.2% to $142.1M.
• · Income from operations swung positive to $34.0M from a loss of $54.1M in FY2025.
• · The effective tax rate was -20.4% in FY2026 versus -4.8% in FY2025.
• · Net cash used in investing activities increased 11.4% to $30.6M.
• · Foreign exchange transaction gain was $3.5M, up from $1.3M.
• · Unrealized gain on derivatives was $1.5M in FY2026 versus $0 in FY2025.
• · The company reported a loss on extinguishment of debt of $9.8M in FY2026.
• · Other expense, net surged to $1.8M from $3K in the prior year.

26-05-2026

OPGEN INC reported total revenue of $30.2M for 2025, a 481% increase from $5.2M in 2024, driven by a 504% surge in listing sponsorship services to $30.2M. However, product sales and laboratory services revenue dropped to zero as the company scaled down legacy operations. Operating expenses increased 27% to $6.2M, while net cash used in operations improved to $1.2M from $4.9M. The company repositioned its business, resulting in a net decrease in cash of $0.7M.

• · Cost of services increased from $1,575 to $3,020,000 (191,646% increase) due to new listing sponsorship business.
• · Gain on extinguishment of debt in 2024 was $9,738,487; no such gain in 2025.
• · Gain on impairment adjustment in 2024 was $2,079,575; none in 2025.
• · Net cash provided by financing activities was $496,719 in 2025 vs $5,028,574 in 2024.
• · Weighted average exercise price of outstanding options is $9.01.
• · No securities remaining available for future issuance under equity compensation plans.

26-05-2026

ConnectM Technology Solutions, Inc. (CNTM) reported a net loss attributable to the company of $6.95M for Q1 2026, slightly improved from a $7.02M loss in Q1 2025. Revenue declined 9.1% year-over-year to $8.17M, while gross profit fell sharply by 38.1% to $1.87M, driven by a 5.6% increase in cost of revenues. The company also recorded a $2.91M loss on disposal of businesses and a $560K foreign currency translation loss, partially offset by a $282K equity in earnings from Sun Solar. Total liabilities rose to $37.86M from $34.59M at year-end 2025, and cash reserves decreased to $2.47M.

• · Total assets increased to $39.82M from $36.17M at year-end 2025, primarily due to a $7.41M equity method investment in Sun Solar.
• · Goodwill decreased sharply from $5.22M to $2.29M, reflecting a disposal of businesses.
• · Total stockholders' deficit improved to $1.96M from $1.58M, but accumulated deficit widened to $68.62M.
• · Net cash used in operating activities was $2.81M, nearly unchanged from $2.83M in Q1 2025.
• · Financing activities provided $2.45M, including $1.61M from convertible notes and $1.32M from debt issuance.
• · The company issued 468,750 shares of common stock for the equity method investment in Sun Solar, valued at $7.13M.
• · A 1-for-32 reverse stock split was effected, reducing outstanding shares from 169,968,082 to 5,312,911.
• · The 'Other' segment holds 76 acres of land in Odisha, India for a multimodal logistics park and AI data center campus, with no revenue generated.

26-05-2026

Hall Chadwick Acquisition Corp (HCACU) reported net income of $1.65M for the three months ended March 31, 2026, and $2.31M since inception (May 22, 2025). The company's cash balance decreased to $463K from $631K at year-end 2025, while cash and investments held in the Trust Account grew to $209.6M. The company remains a pre-business combination SPAC with no operating revenue, and its shareholders' deficit widened to -$5.12M.

• · The company has no operating revenue, with formation, general, and administrative costs of $183K for Q1 2026 and $312K since inception.
• · Interest earned on investments held in Trust Account was $1.84M for Q1 2026 and $2.62M since inception.
• · Basic and diluted net income per share for Class A ordinary shares was $0.08 for Q1 2026 and $0.27 since inception.
• · Basic and diluted net income per share for Class B ordinary shares was $0.21 for Q1 2026 and $0.29 since inception.
• · Total assets were $210.2M as of March 31, 2026, up from $208.6M at December 31, 2025.
• · Total liabilities were $8.32M as of March 31, 2026, down slightly from $8.34M at year-end 2025.
• · Net cash used in operating activities was $173K for Q1 2026 and $364K since inception.
• · The company's shareholders' deficit improved from -$6.78M at December 31, 2025 to -$5.12M at March 31, 2026, primarily due to accumulated profit.

26-05-2026

Hubilu Venture Corp (HBUV) reported a net loss of $172,177 for Q1 2026, a significant improvement from a net loss of $322,560 in Q1 2025, driven by a 54.8% increase in rental revenue to $593,738. However, total liabilities exceeded total assets, resulting in a stockholders' deficit of $1,934,925 as of March 31, 2026, compared to a deficit of $1,777,646 at year-end 2025. Cash increased to $151,782 from $52,071, but operating cash flow remained negative at ($60,067).

• · Net operating income improved to $250,244 in Q1 2026 from $47,802 in Q1 2025.
• · Interest expense increased to $396,003 from $353,842 year-over-year.
• · Total liabilities increased to $25,506,825 from $25,312,016 at year-end 2025.
• · Operating cash flow was negative ($60,067) in Q1 2026, compared to negative ($128,846) in Q1 2025.
• · Capital expenditures were $15,357 in Q1 2026, down from $65,538 in Q1 2025.
• · The company had a working capital deficit of $1,425,714 as of March 31, 2026 (current liabilities of $1,645,958 exceeded current assets of $220,244).

26-05-2026

Apimeds Pharmaceuticals US reported a net loss of $35.1M for Q1 2026, a significant increase from a $0.4M loss in Q1 2025, driven by a $22.1M unrealized loss on digital assets and a surge in operating expenses to $12.2M (from $0.4M). Total assets decreased to $141.2M from $164.2M at year-end 2025, primarily due to a decline in digital asset values. Cash and cash equivalents fell to $0.98M from $1.64M, though restricted cash remained at $8.0M.

• · The company holds digital assets (BTC, USDT, NILA Tokens) measured at fair value, with BTC and USDT classified as Level 1 and NILA Tokens as Level 2.
• · Unrealized loss on digital assets was $22.1M for Q1 2026, while realized gain on sale was only $15,100.
• · Research and development expenses were $901,144 in Q1 2026 vs. $0 in Q1 2025, indicating new R&D activity.
• · General and administrative expenses surged to $11.3M from $0.4M, likely due to advisory shares and other costs.
• · The company issued $8.1M in common shares to be issued in connection with an advisory agreement.
• · Convertible notes increased to $7.9M from $7.1M, with accretion of $851,018.
• · Notes payable increased by $920,000 in Q1 2026, with proceeds of $995,000 and issuance costs of $75,000.
• · The company had no revenue reported for either period.
• · Cash used in operating activities was $2.1M, up from $20,313 in the prior year.
• · The company's accumulated deficit grew to $45.5M from $10.4M at year-end 2025.